Zhejiang Hisun Pharmaceutical Future Growth

Future criteria checks 3/6

Zhejiang Hisun Pharmaceutical is forecast to grow earnings and revenue by 50.1% and 12.4% per annum respectively. EPS is expected to grow by 50% per annum. Return on equity is forecast to be 7.6% in 3 years.

Key information

50.1%

Earnings growth rate

50.0%

EPS growth rate

Pharmaceuticals earnings growth	19.0%
Revenue growth rate	12.4%
Future return on equity	7.6%
Analyst coverage	Low
Last updated	22 Mar 2024

Recent future growth updates

Recent updates

These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well

Apr 30

Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel

Mar 29

Earnings and Revenue Growth Forecasts

SHSE:600267 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	14,245	550	N/A	N/A	1
12/31/2025	14,242	757	N/A	2,103	2
12/31/2024	13,268	648	N/A	1,023	2
3/31/2024	10,036	-77	1,390	1,513	N/A
12/31/2023	10,373	-93	1,263	1,503	N/A
9/30/2023	11,994	615	1,539	1,909	N/A
6/30/2023	12,360	589	1,339	1,759	N/A
3/31/2023	12,123	586	1,607	2,084	N/A
12/31/2022	12,037	489	1,535	2,066	N/A
9/30/2022	11,773	319	1,507	2,163	N/A
6/30/2022	11,869	526	1,792	2,456	N/A
3/31/2022	12,046	496	1,131	1,793	N/A
12/31/2021	12,136	487	1,114	1,737	N/A
9/30/2021	12,308	574	889	1,363	N/A
6/30/2021	12,040	457	659	1,184	N/A
3/31/2021	11,923	614	663	1,296	N/A
12/31/2020	11,354	417	898	1,590	N/A
9/30/2020	10,914	-819	687	1,362	N/A
6/30/2020	10,724	281	104	1,019	N/A
3/31/2020	10,774	-10	234	1,124	N/A
12/31/2019	11,072	93	-378	698	N/A
9/30/2019	10,694	755	-691	1,098	N/A
6/30/2019	10,522	-455	-335	1,424	N/A
3/31/2019	10,163	-472	-612	1,259	N/A
12/31/2018	10,187	-492	-303	1,446	N/A
9/30/2018	10,200	16	390	1,672	N/A
6/30/2018	10,398	15	501	1,608	N/A
3/31/2018	10,655	18	191	1,554	N/A
12/31/2017	10,572	14	N/A	1,353	N/A
9/30/2017	10,574	-120	N/A	963	N/A
6/30/2017	10,509	-101	N/A	835	N/A
3/31/2017	10,090	-94	N/A	840	N/A
12/31/2016	9,733	-94	N/A	776	N/A
9/30/2016	9,396	40	N/A	594	N/A
6/30/2016	8,986	-3	N/A	413	N/A
3/31/2016	8,793	15	N/A	593	N/A
12/31/2015	8,767	14	N/A	736	N/A
9/30/2015	9,382	85	N/A	637	N/A
6/30/2015	9,835	175	N/A	775	N/A
3/31/2015	10,145	237	N/A	697	N/A
12/31/2014	10,097	308	N/A	571	N/A
9/30/2014	9,645	314	N/A	963	N/A
6/30/2014	9,104	311	N/A	461	N/A
3/31/2014	8,895	303	N/A	630	N/A
12/31/2013	8,604	302	N/A	527	N/A
9/30/2013	7,785	268	N/A	104	N/A
6/30/2013	7,178	291	N/A	454	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600267 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).

Earnings vs Market: 600267 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 600267 is expected to become profitable in the next 3 years.

Revenue vs Market: 600267's revenue (12.4% per year) is forecast to grow slower than the CN market (14.7% per year).

High Growth Revenue: 600267's revenue (12.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 600267's Return on Equity is forecast to be low in 3 years time (7.6%).

Zhejiang Hisun Pharmaceutical Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Price target decreased by 13% to CN¥8.30

Recent updates

Zhejiang Hisun Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well

Full year 2023 earnings released: CN¥0.08 loss per share (vs CN¥0.42 profit in FY 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel

Investor sentiment deteriorates as stock falls 17%

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Price target decreased by 13% to CN¥8.30

New minor risk - Financial position

Third quarter 2023 earnings released: EPS: CN¥0.031 (vs CN¥0.01 in 3Q 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Full year 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.43 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.19 in 3Q 2021)

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) announces an Equity Buyback for CNY 195 million worth of its shares.

Taizhou Jiaojiang State Owned Asset Operation Group Co Ltd agreed to acquire 4% stakes in Zhejiang Hisun Animal Health-care Products Co., Ltd. from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for CNY 100 million.

Second quarter 2022 earnings released: EPS: CN¥0.27 (vs CN¥0.13 in 2Q 2021)

Shanghai Yuanxun Enterprise Management Center and Hong Kong Summit Nutrition Limited agreed to acquire 34.72% interest of Zhejiang Hisun Sulikang Biotechnology Co., Ltd from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for RMB 17.4 million.

Investor sentiment improved over the past week

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.43 (vs CN¥0.43 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.11 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.32 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.074 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.096 in FY 2019)

New 90-day low: CN¥15.49

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: CN¥18.41

CHIPSCREEN and HISUN Reach A Strategic Cooperation

New 90-day low: CN¥15.63

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) signed letter of intent to acquire the remaining 49% stake in Hanhui Pharmaceutical Co., Ltd. from Hillhouse Capital Management, Ltd for CNY 4.4 billion.

Earnings released

New 90-day high - CN¥18.90

Zhejiang Hisun Pharmaceutical Co., Ltd. announced a financing transaction

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies